Acalabrutinib, venetoclax, and obinutuzumab as frontline treatment for chronic lymphocytic leukaemia: a single-arm, open-label, phase 2 studyMatthew S. Davids, Jennifer R. Brown, Benjamin L. Lampson et al.|The Lancet Oncology|2021Cited by 102
Phase II Study of Acalabrutinib, Venetoclax, and Obinutuzumab in a Treatment-Naïve Chronic Lymphocytic Leukemia Population Enriched for High-Risk DiseaseMatthew S. Davids, Jennifer R. Brown, Benjamin L. Lampson et al.|Journal of Clinical Oncology|2024Cited by 40
Preliminary Safety and Efficacy Results from a Phase 2 Study of Acalabrutinib, Venetoclax and Obinutuzumab in Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL)Benjamin L. Lampson, Matthew S. Davids, Svitlana Tyekucheva et al.|Blood|2019Cited by 31
Updated Results from a Multicenter, Phase 2 Study of Acalabrutinib, Venetoclax, Obinutuzumab (AVO) in a Population of Previously Untreated Patients with CLL Enriched for High-Risk DiseaseChristine E. Ryan, Matthew S. Davids, Benjamin L. Lampson et al.|Blood|2022Cited by 23
Updated Safety and Efficacy Results from a Phase 2 Study of Acalabrutinib, Venetoclax and Obinutuzumab (AVO) for Frontline Treatment of Chronic Lymphocytic Leukemia (CLL)Matthew S. Davids, Jennifer R. Brown, Benjamin L. Lampson et al.|Blood|2020Cited by 19